Anti-alpha5beta1 Antibodies for Angiogenesis Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective targeting and inhibition of α5β1 integrin, which is elevated in tumor vascular endothelium and involved in angiogenesis, necessitating improved compositions and methods for therapeutic and diagnostic applications.
Innovation Solution
Development of novel anti-α5β1 integrin antibodies derived from the 7H5 hybridoma with enhanced binding affinity, including humanized variants that can be conjugated with therapeutic agents or markers for use in treating abnormal angiogenesis, neoplasia, and autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-α5β1 integrin antibodies are used, then basic targeting capability is achieved, but binding affinity is insufficient for effective therapeutic and diagnostic applications
Solution Approach 1:
The patent applies parameter changes by modifying the antibody sequence parameters through humanization and affinity maturation processes. Specific amino acid substitutions were made in the variable regions (LHVR1, LHVR2, LHVR3, HHVR1, HHVR2, HHVR3) to enhance binding affinity while maintaining the fundamental antibody structure and manufacturability.
Solution Approach 2:
The patent creates composite antibody structures by combining human framework regions with modified complementarity-determining regions (CDRs). The humanized antibody format integrates human constant regions with engineered variable regions, creating a composite molecule that combines reduced immunogenicity with enhanced binding properties.
2Reliability
If α5β1 integrin is targeted to inhibit angiogenesis, then anti-angiogenic effects are achieved, but combination therapy complexity increases
Solution Approach 1:
The patent segments the anti-angiogenic therapy by separating the VEGF pathway inhibition (via VEGF antagonists) from the integrin pathway inhibition (via anti-α5β1 antibodies). This allows each mechanism to be optimized independently while working synergistically, with the anti-α5β1 antibody providing a distinct mechanism of action that complements VEGF inhibition.
Solution Approach 2:
The anti-α5β1 antibody provides multi-functional utility by serving both as a standalone anti-angiogenic agent and as a synergistic partner with VEGF antagonists. The antibody can be used in combination therapies for cancer and other diseases involving abnormal angiogenesis, offering versatile application across multiple disease indications.
Data Source
Figure 1
Figure 2
Figure 3A~5
AI summary
The present invention relates to the use of VEGF antagonists and a novel anti-a5ß1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-a5ß1 antibodies and methods of making and using them.